Active Ingredient History
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Myelodysplastic Syndromes (approved 2020)
BRCA1 Protein (Phase 1)
Breast Neoplasms (Phase 1)
Fusion Proteins, bcr-abl (Phase 2)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 1)
Leukemia (Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2/Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoma, T-Cell (Phase 1/Phase 2)
Melanoma (Phase 1/Phase 2)
Mesothelioma (Phase 2)
Mutation (Phase 1)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 1)
Nerve Sheath Neoplasms (Phase 2)
Neuroendocrine Tumors (Phase 1)
Patient Preference (Phase 3)
Triple Negative Breast Neoplasms (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue